MRI Scan Tests Liver Scarring in Chronic Hepatitis B
Studies an MRI-based scan to measure liver scarring in people with hepatitis B.
Plain-language title generated from the registry record
Registry title: MR Elastography for Assessing Liver Fibrosis in Chronic Hepatitis B
Key facts
- Where
- Shenyang, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06779058, who can take part
Where in China
- Shengjing HospitalShenyang, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shengjing Hospital
- Trial code
- NCT06779058
- Record updated
- 27 February 2026
- Original description
How to construct a non-invasive, accurate, and convenient method to evaluate the severity of liver fibrosis (LF) is an important general problem in the management of patients with chronic hepatitis B (CHB). We plan to investigate the ability of magnetic resonance elastography (MRE) to grade fibrosis in chronic hepatitis B and apply to clinical longitudinal follow-up.Read full original descriptionShow less
Retrospective and Prospective Multi-center Clinical Study of Magnetic Resonance Elastography in Evaluating Hepatic Fibrosis in Chronic Viral Hepatitis B
How to construct a non-invasive, accurate, and convenient method to evaluate the severity of liver fibrosis (LF) is an important general problem in the management of patients with chronic hepatitis B (CHB). We plan to investigate the ability of magnetic resonance elastography (MRE) to grade fibrosis in chronic hepatitis B and apply to clinical longitudinal follow-up.
Inclusion: Age ≥ 18 years old; Confirmed CHB (laboratory, imaging and clinical tests); MRE within 6 months before and after liver biopsy; Treatment-naïve; Child-Pugh Grade A (<7 points); Written informed consent in prospective follow-up cohort.
Exclusion: Patients with liver malignant tumor; Chronic hepatitis due to other causes (such as alcoholic hepatitis); CHB combined with hepatitis C, hepatitis D, or HIV; Patients with biliary tract diseases; Contraindications of MRE examination, MRE failure; Poor pathological effect.